RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCOPUS

      보조생식술 주기에서의 과배란유도를 위한 재조합 황체화호르몬의 효용성 = Efficacy of Recombinant Luteinizing Hormone for Controlled Ovarian Hyperstimulation in Assisted Reproduction Cycles

      한글로보기

      https://www.riss.kr/link?id=A100815973

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      참고문헌 (Reference)

      1 Lisi F, "Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study" 3 : 190-194, 2001

      2 Tarlatzis B, "The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study" 21 : 90-94, 2006

      3 Filicori M, "The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction" 8 : 543-557, 2002

      4 Shoham Z, "The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering" 64 : 237-251, 1995

      5 Balasch J, "The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction" 18 : 250-256, 2001

      6 Yanaihara A, "The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome" 25 : 115-118, 2008

      7 Shoham Z, "The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation" 77 : 1170-1177, 2002

      8 Gadkari RA, "The antigen binding sites of various hCG monoclonal antibodies show homology to different domains of LH receptor" 260-262, 2007

      9 De Placido G, "Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH" 16 : 1875-1879, 2001

      10 Gutman G, "Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis" 89 : 922-926, 2008

      1 Lisi F, "Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study" 3 : 190-194, 2001

      2 Tarlatzis B, "The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study" 21 : 90-94, 2006

      3 Filicori M, "The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction" 8 : 543-557, 2002

      4 Shoham Z, "The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering" 64 : 237-251, 1995

      5 Balasch J, "The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction" 18 : 250-256, 2001

      6 Yanaihara A, "The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome" 25 : 115-118, 2008

      7 Shoham Z, "The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation" 77 : 1170-1177, 2002

      8 Gadkari RA, "The antigen binding sites of various hCG monoclonal antibodies show homology to different domains of LH receptor" 260-262, 2007

      9 De Placido G, "Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH" 16 : 1875-1879, 2001

      10 Gutman G, "Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis" 89 : 922-926, 2008

      11 Chappel SC, "Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process" 6 : 1206-1212, 1991

      12 Al-Inany H, "Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception" 20 : 2061-2073, 2005

      13 Griesinger G, "Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol" 20 : 1200-1206, 2005

      14 Gutman G, "Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity" 2008

      15 De Placido G, "Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial" 20 : 390-396, 2005

      16 Cedrin-Durnerin I, "Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study" 19 : 1979-1984, 2004

      17 Levi-Setti PE, "Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH" 126 : 212-216, 2006

      18 Mochtar MH, "Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles" 2007

      19 Baruffi RL, "Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis" 14 : 14-25, 2007

      20 Marrs R, "Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment" 8 : 175-182, 2004

      21 Reame N, "Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormone secretion" 59 : 328-337, 1984

      22 Kolibianakis EM, "Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF" 19 : 2490-2496, 2004

      23 Barrenetxea G, "Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles" 89 : 546-553, 2008

      24 Themmen APN, "Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function" 21 : 551-583, 2000

      25 Acevedo B, "Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles" 82 : 343-347, 2004

      26 Ruvolo G, "Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures" 87 : 542-546, 2007

      27 Filicori M, "Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis" 78 : 414-416, 2002

      28 Hurwitz JM, "Inhibins, activins, and follistatin in the aging female and male" 22 : 209-217, 2004

      29 Westergaard LG, "Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction" 15 : 1003-1008, 2000

      30 Garcia-Velasco JA, "High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist" 15 : 280-287, 2007

      31 De Placido G, "Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response" 85 : 247-250, 2006

      32 Fair T, "Follicular oocyte growth and acquisition of developmental competence" 78 : 203-216, 2003

      33 Hillier SG, "Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited" 100 : 51-54, 1994

      34 O'Dea L, "Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect" 2008

      35 Ferraretti AP, "Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques" 82 : 1521-1526, 2004

      36 Lisi F, "Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization" 83 : 309-315, 2005

      37 Chung K, "Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists" 84 : 313-318, 2005

      38 Liu KE, "Elevated day 3 follicle-stimulating hormone/luteinizing hormone ratio >or= 2 is associated with higher rates of cancellation in in vitro fertilization-embryo transfer cycles" 90 : 297-301, 2008

      39 Fabregues F, "Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age" 85 : 925-931, 2006

      40 Durnerin CI, "Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation" 23 : 421-426, 2008

      41 Humaidan P, "Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study" 8 : 635-643, 2004

      42 De Placido G, "Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation" 60 : 637-643, 2004

      43 Huirne JA, "Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy" 20 : 359-367, 2005

      44 Orvieto R, "Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?" 2008

      45 Grondahl ML, "Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin" 2008

      46 Alviggi C, "De Placido G. Exploiting LH in ovarian stimulation" 12 : 221-233, 2006

      47 Filicori M, "Current concepts and novel applications of LH activity in ovarian stimulation" 14 : 267-273, 2003

      48 Sauer MV, "Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction" 9 : 487-493, 2004

      49 Kolibianakis EM, "Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review" 12 : 3-12, 2006

      50 Kolibianakis EM, "Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis" 13 : 445-452, 2007

      51 Sills ES, "A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization" 14 : 2230-2235, 1999

      52 Ku SY, "A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction" 109 : 55-59, 2003

      53 The ganirelix dose-finding study group, "A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)" 13 : 3023-3031, 1998

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2024 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2021-01-01 평가 등재학술지 선정 (해외등재 학술지 평가) KCI등재
      2020-12-01 평가 등재후보로 하락 (해외등재 학술지 평가) KCI등재후보
      2012-01-05 학술지명변경 한글명 : 대한생식의학회지 -> Clinical and Experimental Reproductive Medicine
      외국어명 : The Korean Journal of Reproductive Medicine -> Clinical and Experimental Reproductive Medicine
      KCI등재
      2010-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2007-08-28 학술지명변경 한글명 : 대한불임학회지 -> 대한생식의학회지
      외국어명 : The Korean Journal of Fertility and Sterility -> The Korean Journal of Reproductive Medicine
      KCI등재
      2007-08-28 학회명변경 한글명 : 대한불임학회 -> 대한생식의학회
      영문명 : Korean Society For Fertility And Sterility -> The Korean Society for Reproductive Medicine
      KCI등재
      2007-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2006-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2004-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0 0 0
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0 0 0 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼